# HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

> **NCT05535933** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hutchmed** · enrollment: 111 (actual)

## Conditions studied

- Warm Antibody Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** HMPL-523(300mg PO QD)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05535933
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-30
- **Primary completion:** 2025-11-25
- **Final completion:** 2026-11
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05535933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05535933, "HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05535933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*